Retrospective Study Evaluating ABRYSVO® Vaccine Effectiveness Against Severe Lower Respiratory Tract Disease in Older Adults

First published: 24/04/2025

Last updated: 24/04/2025

Study Ongoing

Administrative details

EU PAS number

EUPAS1000000460

Study ID

1000000460

DARWIN EU® study

No

Study countries

☐ United States

Study status

Ongoing

Contact details

Study institution contact

Sabrina Welsh sabrina.welsh@pfizer.com

Study contact

sabrina.welsh@pfizer.com

Primary lead investigator

Sara Tartof

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 11/09/2023

Actual: 11/09/2023

Study start date

Planned: 01/11/2023

Actual: 01/11/2023

Date of final study report

Planned: 01/09/2029

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

C3671030

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Study drug and medical condition

Name of medicine

ABRYSVO

Anatomical Therapeutic Chemical (ATC) code

(J07BX05) respiratory syncytial virus vaccines

respiratory syncytial virus vaccines

Medical condition to be studied

Lower respiratory tract infection

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown